Artificial intelligence-based radiographic extent analysis to predict tuberculosis treatment outcomes: a multicenter cohort study

Sci Rep. 2024 Jun 7;14(1):13162. doi: 10.1038/s41598-024-63885-0.

Abstract

Predicting outcomes in pulmonary tuberculosis is challenging despite effective treatments. This study aimed to identify factors influencing treatment success and culture conversion, focusing on artificial intelligence (AI)-based chest X-ray analysis and Xpert MTB/RIF assay cycle threshold (Ct) values. In this retrospective study across six South Korean referral centers (January 1 to December 31, 2019), we included adults with rifampicin-susceptible pulmonary tuberculosis confirmed by Xpert assay from sputum samples. We analyzed patient characteristics, AI-based tuberculosis extent scores from chest X-rays, and Xpert Ct values. Of 230 patients, 206 (89.6%) achieved treatment success. The median age was 61 years, predominantly male (76.1%). AI-based radiographic tuberculosis extent scores (median 7.5) significantly correlated with treatment success (odds ratio [OR] 0.938, 95% confidence interval [CI] 0.895-0.983) and culture conversion at 8 weeks (liquid medium: OR 0.911, 95% CI 0.853-0.973; solid medium: OR 0.910, 95% CI 0.850-0.973). Sputum smear positivity was 49.6%, with a median Ct of 26.2. However, Ct values did not significantly correlate with major treatment outcomes. AI-based radiographic scoring at diagnosis is a significant predictor of treatment success and culture conversion in pulmonary tuberculosis, underscoring its potential in personalized patient management.

Keywords: Artificial intelligence; Pulmonary; Radiography; Thoracic; Treatment outcome; Tuberculosis.

Publication types

  • Multicenter Study

MeSH terms

  • Adult
  • Aged
  • Antitubercular Agents / therapeutic use
  • Artificial Intelligence*
  • Female
  • Humans
  • Male
  • Middle Aged
  • Mycobacterium tuberculosis / drug effects
  • Mycobacterium tuberculosis / isolation & purification
  • Radiography, Thoracic / methods
  • Republic of Korea
  • Retrospective Studies
  • Rifampin / therapeutic use
  • Sputum* / microbiology
  • Tomography, X-Ray Computed / methods
  • Treatment Outcome
  • Tuberculosis, Pulmonary* / diagnostic imaging
  • Tuberculosis, Pulmonary* / drug therapy

Substances

  • Rifampin
  • Antitubercular Agents